iBio Inc.

News & Events

Press Releases

In The Media

1. iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

   GlobeNewswire MAY 5, 2025 8:00 AM EDT
   Activin E antibody demonstrates significant decrease in fat in obese mice by reducing visceral fa...
   READ ARTICLE

2. iBio Reports Fiscal Third Quarter 2025 Financial Results

   GlobeNewswire MAY 2, 2025 8:00 AM EDT
   SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq:IBIO), today reported financial re...
   READ ARTICLE

3. iBio Raises $6.2 Million Through Warrant Inducement Transaction

   GlobeNewswire APR 29, 2025 1:43 PM EDT
   SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO) (“iBio” or ...
   READ ARTICLE

4. iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

   GlobeNewswire APR 22, 2025 8:00 AM EDT
   SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Bio, Inc. (Nasdaq: IBIO), an AI-driven innovato...
   READ ARTICLE

5. iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

   GlobeNewswire APR 7, 2025 7:00 AM EDT
   Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-actin...
   READ ARTICLE

6. iBio to Begin Trading on the Nasdaq Stock Exchange

   GlobeNewswire FEB 19, 2025 4:05 PM EST
   SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innova...
   READ ARTICLE

7. iBio Reports Fiscal Second Quarter 2025 Financial Results

   GlobeNewswire FEB 10, 2025 4:05 PM EST
   SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), today reported financial re...
   READ ARTICLE

8. iBio Announces New Investments from Board Members and Officers

   GlobeNewswire JAN 13, 2025 7:00 AM EST
   SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innov...
   READ ARTICLE

9. iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio

   GlobeNewswire JAN 7, 2025 7:00 AM EST
   SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator...
   READ ARTICLE

10. iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

    GlobeNewswire JAN 2, 2025 7:00 AM EST
    SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc . (NYSEA: IBIO), an AI-driven innovato...
    READ ARTICLE